Expansion in drug development GBT Germany GmbH is actively developing treatments for beta thalassemia and sickle cell disease, presenting a sales opportunity for pharmaceutical partnerships in the emerging field of blood disorder therapeutics.
Acquisition by Pfizer-BioNTech The recent acquisition of GBT Germany GmbH by Pfizer-BioNTech for $5.4 billion indicates a strong financial backing, potentially opening doors for collaboration and sales synergies within the pharmaceutical industry.
Launch of Phase 3 clinical trial GBT Germany GmbH's initiation of the international Phase 3 HOPE-KIDS 2 study for sickle cell disease represents a chance for clinical trial partnerships and sales of innovative treatments in the pediatric healthcare segment.
Environmental focus and ESG report With the release of its inaugural environmental, social, and governance (ESG) report, GBT Germany GmbH showcases its commitment to sustainable value creation, offering potential sales opportunities in the ESG-conscious market segment.
Revenue and funding status Having a revenue range of $50-100 million and funding of $300 million positions GBT Germany GmbH as a financially stable entity, indicating potential for procurement and sales collaboration with suppliers and service providers.
501
$100M$1B
436$50M$100M
334$50M$100M
1.5K$100M$1B
122$10M$50MGlobal Blood Therapeutics uses 8 technology products and services including Google Analytics, React, Backbone.js, and more. Explore Global Blood Therapeutics's tech stack below.
| Global Blood Therapeutics Email Formats | Percentage |
| FLast@gbt.com | 93% |
| Last@gbt.com | 3% |
| FirstL@gbt.com | 3% |
| FL@gbt.com | 1% |
| FLast@globalbloodtx.com | 86% |
| First.Last@globalbloodtx.com | 9% |
| LastFirst@globalbloodtx.com | 2% |
| LFirst@globalbloodtx.com | 2% |
| F.Last@globalbloodtx.com | 1% |
Biotechnology ResearchCalifornia, United States201-500 Employees
Global Blood Therapeutics (GBT) is now part of Pfizer, and we look forward to continuing our mission on behalf of people living with sickle cell disease. The Global Blood Therapeutics page will no longer be active or monitored. Please follow Pfizer for new content.
Company Overview
Media & News
Funding & FinancialsGlobal Blood Therapeutics has raised a total of $300M of funding over 7 rounds. Their latest funding round was raised on Dec 15, 2021 in the amount of $300M.
Global Blood Therapeutics's revenue is in the range of $50M$100M
Funding & FinancialsGlobal Blood Therapeutics has raised a total of $300M of funding over 7 rounds. Their latest funding round was raised on Dec 15, 2021 in the amount of $300M.
Global Blood Therapeutics's revenue is in the range of $50M$100M
1-888-653-2347 
support@leadiq.com